BaseCase was founded in 2007 by Gijs Hubben (from ‘s-Hertogenbosch, the Netherlands) and Diarmuid Glynn (from Galway, Ireland). Gijs is a pharmacologist and health economist, while Diarmuid has a background in mathematics and computer science. The founders discovered Berlin to be the ideal place to start BaseCase: an attractive European capital, boasting an abundance of international talent and a reliable infrastructure.
The first product iteration enabled online access to pharma cost-effectiveness models to improve communication with payers. This approach resonated within the life sciences industry and our first customers soon began to reap the benefits. Following a major investment in 2010 from VC fund HTGF (exiting in 2015) and the Investment Bank Berlin, we extended our original focus on market access to address the needs of commercial and medical affairs teams. Through close relationships with our customers, a talented staff, and a creative environment, the product evolved over time into the fully-featured customer engagement platform that it is today.
The three major trends in the healthcare industry that have been the driving force behind BaseCase over the years still persist: increasing pressure on healthcare budgets, decentralization in healthcare decision making, and the extensive use of tablet devices by field teams. As the company has grown and responded to these trends, BaseCase is now uniquely placed to support the life sciences industry with our proprietary SaaS platform.
Today, we are very proud that our technology is used every day by field teams within the top-ten global pharmaceutical and medtech companies, and that we have been honored as one of Berlin’s most successful technology companies by German Vice-Chancellor, Sigmar Gabriel.
In February 2018 BaseCase has joined the Certara family. Certara is the global leader in model-informed drug development, regulatory science, real-world evidence and market access services.